Adherence to treatment of latent tuberculosis infection in a clinical population in New York City

International Journal of Infectious Diseases

Volumn 14, Issue 4, 2010, Pages

  Li, Jiehui ^a   Munsiff, Sonal S ^a,b   Tarantino, Tania ^a   Dorsinville, Marie ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adherence; Latent TB infection; Treatment; Tuberculosis prevention

Indexed keywords

ISONIAZID; RIFABUTIN; RIFAMPICIN; RIFAMYCIN;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DIRECTLY OBSERVED THERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PROPHYLAXIS; PUBLIC HEALTH SERVICE; RISK FACTOR; TUBERCULOSIS; UNITED STATES; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MEDICATION ADHERENCE; MYCOBACTERIUM TUBERCULOSIS; NEW YORK CITY; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RIFAMPIN; YOUNG ADULT;

EID: 77949491464     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.05.007     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000; 49 (RR-6): 1-51.
2. US Department of Health and Human Services. Healthy people 2010: understanding and improving health. 2nd ed. Washington, DC: GPO; 2000. Available at: http://www.healthypeople.gov/document/html/objectives/14-13.htm (accessed June 2009).
3. Reichler M.R., Reves R., Bur S., Ford J., Thompson V., Mangura B., et al. Contact Investigation Study Gr oup. Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J 95 (2002) 414-420
4. Marks S.M., Taylor Z., Qualls N.L., Shrestha-Kuwahara R.J., Wilce M.A., and Nguyen C.H. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 162 (2000) 2033-2038
5. Leary L, Jereb J, Taylor Z. Aggregate reports for tuberculosis program evaluation (ARPEs), United States 2000-2001, follow-up and treatment for contacts to tuberculosis cases (Abstract). Presented at the National TB Controller Meeting, June 2005. Atlanta, GA, USA.
6. Menzies D., Dion M.J., Rabinovitch B., Mannix S., Brassard P., and Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170 (2004) 445-449
7. Page K.R., Sifakis F., Montes de Oca R., Cronin W.A., Doherty M.C., Federline L., et al. Improved adherence and less toxicity with rifampin vs. isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 166 (2006) 1863-1870
8. Lardizabal A., Passannante M., Kojakali F., Hayden C., and Reichman L.B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 130 (2006) 1712-1717
9. Menzies D., Dion M.J., Francis D., Parisien I., Rocher I., Mannix S., et al. In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. Int J Tuberc Lung Dis 9 (2005) 1343-1348
10. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 160 (2004) 301-305
11. Spiegelman D., and Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 162 (2005) 199-205
12. Lashley M. A targeted testing program for tuberculosis control and prevention among Baltimore city's homeless population. Public Health Nurs 24 (2007) 34-39
13. Shieh F.K., Snyder G., Horsburgh C.R., Bernardo J., Murphy C., and Saukkonen J.J. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 174 (2006) 717-721
14. Nijland H.M., Ruslami R., Stalenhoef J.E., Nelwan E.J., Alisjahbana B., Nelwan R.H., et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 43 (2006) 848-854
15. Centers for Disease Control and Prevention (CDC). Notice to readers: updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2004; 53: 37.
16. Reichman L.B., Lardizabal A., and Hayden C.H. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 170 (2004) 832-835
17. Ferebee S.H. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 17 (1970) 28-106
18. Comstock G.W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 3 (1999) 847-850
19. Polesky A., Farber H.W., Gottlieb D.J., Park H., Levinson S., O'Connell J.J., et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 154 (1996) 1473-1477
20. Villarino M.E., Ridzon R., Weismuller P.C., Elcock M., Maxwell R.M., Meador J., et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 155 (1997) 1735-1738
21. Sterling T.R. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med 29 (2008) 532-541
22. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 147 (1993) 1311-1320
23. Donovan J.L., and Blake D.R. Patient non-compliance: deviance or reasoned decision-making?. Soc Sci Med 34 (1992) 507-513
24. Grange J.M., and Festenstein F. The human dimension of tuberculosis control. Tuber Lung Dis 74 (1993) 219-222
25. Glassroth J. The physician's role in tuberculosis prevention. Clin Chest Med 10 (1989) 365-374
26. Davidson B.L. A controlled comparison of directly observed therapy vs. self-administered therapy for active tuberculosis in the urban United States. Chest 114 (1998) 1239-1243
27. Chaisson R.E., Barnes G.L., Hackman J., Watkinson L., Kimbrough L., Metha S., et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med 110 (2001) 610-615
28. Malotte C.K., Hollingshead J.R., and Larro M. Incentives vs. outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med 20 (2001) 103-107
29. Nyamathi A.M., Christiani A., Nahid P., Gregerson P., and Leake B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis 10 (2006) 775-782
30. Haynes R.B., Ackloo E., Sahota N., McDonald H.P., and Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2 (2008) CD000011